Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended September 30, 2025. ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 000-10843 CSP Inc. (Exact name of Registrant as specified in its Charter) Massachusetts 04-2441294 (State or other jurisdiction of ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended November 1, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ____________ to ____________ Commission file number 0-23071 THE CHILDREN'S PLACE, INC. (Exact name of registrant as specified in its chart ...

Technology and Development - The company has a proprietary FHAB® technology platform designed to enhance drug accumulation in tumors and extend the duration of activity in the body, with a U.S. patent received in June 2021[13]. - The proprietary FHAB technology allows for the production of compounds with extended serum half-lives and improved tissue accumulation compared to naked recombinant cytokines[44]. - Preclinical studies indicated that mIL12-FHAB achieved a 30-to-50-fold increase in tumor reduction compared to standalone mIL-12 in mouse models[53]. - Biodistribution studies indicated that mIL12-FHAB had 2.5-4.7 times higher tumor accumulation compared to mIL-12, suggesting enhanced targeting[63]. - The company is exploring amino acid modifications to IL-18 to enhance its therapeutic potential against cancer[110]. Clinical Trials and Programs - The lead asset, SON-1010, is in clinical development for solid tumors, with a completed non-human primate toxicity study and FDA clearance for the IND application in March 2022[16]. - In the Phase 1 SB101 trial, clinical benefit was observed in 48% of patients overall and 83% at the highest dose of 1200 ng/kg, with one patient showing a partial response[20]. - The company has dosed 103 patients and healthy volunteers with SON-1010 across three Phase 1 studies, with no dose-limiting toxicity reported[22]. - A collaboration with Roche for the clinical evaluation of SON-1010 in combination with atezolizumab is ongoing, with an expansion cohort added to the study[18]. - The SON-080 program for Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Diabetic Peripheral Neuropathy (DPN) has been initiated, with a Phase 1b/2a trial started in October 2022[24]. - The SB211 study for SON-080 confirmed tolerability in initial patients, allowing progression to Phase 2 trials for neuropathy indications[24]. - The SON-1210 program, targeting solid tumors, has completed IND-enabling toxicology studies and is prepared for commercial development pending partnership activity[18]. - Phase 1 clinical trial for SON-1210 in solid tumors is expected to report topline efficacy data in H2 2025[28]. - The Phase 1b/2a trial of SON-1010 in combination with atezolizumab is ongoing, with no dose-limiting toxicities reported to date[72]. - The Sarcoma Oncology Center will conduct a Phase 1b/2a study of SON-1210 in pancreatic cancer, a significant unmet medical need[127]. Financials and Funding - The company reported net losses of approximately $16.0 million and $7.4 million for the fiscal years ended September 30, 2025 and 2024, respectively[205]. - As of September 30, 2025, the company had an accumulated deficit of approximately $133.7 million[205]. - The company has not yet commercialized any products or generated revenue from product sales[206]. - The company anticipates increased expenses as it continues to develop and conduct clinical trials for its product candidates[207]. - In the fourth quarter of 2025, holders exercised warrants to purchase 3,744,624 shares, generating gross proceeds of $11.2 million[191]. - In July 2025, the Company raised $2.0 million through a private placement of zero-interest convertible notes, convertible into 1,730,104 shares at $1.156 per share[192]. - The company raised an aggregate of $5.5 million in a private placement of Series 5 Convertible Preferred Stock, convertible at $1.25 per share[193]. - The November 2024 underwritten public offering generated net proceeds of approximately $4.2 million after deducting underwriting discounts and commissions[197]. - The company received a notice from Nasdaq on May 30, 2025, indicating non-compliance with the minimum stockholders' equity requirement of $2.5 million[198]. Partnerships and Collaborations - The company has entered into a licensing agreement with Alkem Laboratories for the development and commercialization of SON-080 in India[25]. - The Alkem Agreement, executed in October 2024, includes a $1.0 million upfront payment and potential milestone payments totaling up to $1.0 million for the commercialization of SON-080 in India[98]. - The New Life Agreement allows for the out-licensing of SON-080 for DPN in 10 ASEAN countries, with potential milestone payments totaling up to $19.0 million and royalties ranging from 12% to 30% on commercial sales[99]. - A collaboration agreement with Janssen Pharmaceuticals was announced to evaluate the efficacy of SON-1010, SON-1210, and SON-1410 in combination with Janssen's proprietary cell therapy assets[123]. Regulatory and Compliance - The company is subject to extensive government regulations regarding the research, development, and marketing of pharmaceutical products[143]. - The FDA typically inspects manufacturing facilities for compliance with cGMP requirements before approving a BLA[154]. - The FDA has 60 days for an initial review of a BLA submission, with a standard application review period of 12 months and 6 months for priority reviews[155]. - Orphan drug designation provides tax credits and market exclusivity for 7 years post-approval for products intended for rare diseases affecting fewer than 200,000 individuals in the U.S.[168]. - The accelerated approval pathway allows for products to be approved based on surrogate endpoints that predict clinical benefit, particularly for serious conditions[160]. Intellectual Property - The company has secured intellectual property protection for its proprietary manufacturing processes and formulations[34]. - The company has five issued patents and has filed applications in nine other major markets, with potential expiration dates ranging from 2038 to 2041[138]. - The company has received multiple patents for its Albumin Binding Domain Fusion Proteins, with U.S. Patent No. 11,028,166 issued on June 8, 2021, and estimated to expire on March 26, 2039[139]. - The company was granted U.S. Patent No. 12,006,361 on June 11, 2024, covering its product candidate SON-1210, a bifunctional version of IL-12 and IL-15[140]. Market Potential and Competition - The prevalence of diabetic peripheral neuropathy (DPN) is estimated to affect 50%-80% of the diabetic population, with projections indicating over 350 million people with diabetes by 2030[83]. - Current treatments for DPN primarily address pain, leaving significant unmet medical needs, which presents high commercial market potential for SON-080[85]. - The company faces significant competition from large pharmaceutical and biotechnology firms, which may have greater financial resources and expertise[119].

Exhibit 99.1 Contact: Ian Frazer Investor Relations Lennar Corporation (305) 485-4129 FOR IMMEDIATE RELEASE Lennar Reports Fourth Quarter and Fiscal 2025 Results 2025 Fourth Quarter Highlights 2025 Fiscal Year Highlights (more) • Net earnings per diluted share of $1.93; $2.03 excluding adjustments of: ◦ $123 million mark-to-market gains on technology investments, and ◦ $156 million one-time loss on previously announced Millrose Properties, Inc. ("Millrose") exchange offer • Net earnings of $490 million • Ne ...

Exhibit 99.1 Contact: Ian Frazer Investor Relations Lennar Corporation (305) 485-4129 FOR IMMEDIATE RELEASE Lennar Reports Fourth Quarter and Fiscal 2025 Results 2025 Fourth Quarter Highlights 2025 Fiscal Year Highlights (more) • Net earnings per diluted share of $1.93; $2.03 excluding adjustments of: ◦ $123 million mark-to-market gains on technology investments, and ◦ $156 million one-time loss on previously announced Millrose Properties, Inc. ("Millrose") exchange offer • Net earnings of $490 million • Ne ...

Financial Performance - Net sales for Q2 2026 were $327.5 million, an increase of 19% compared to Q2 2025[4] - Adjusted net earnings increased by 7% to $32.5 million, while net earnings decreased by 3% to $27.0 million[4] - Adjusted EBITDA grew 8% to $60.5 million, with operating income rising to $12.3 million from $3.5 million in the prior year[4][7] - Free cash flow improved by 15% to $39.1 million, up from $33.9 million in Q2 2025[4][11] - Operating cash flow for the quarter was $51.5 million, a 5% increase from $49.1 million in Q2 2025[4][11] - For the three months ended November 30, 2025, the GAAP net earnings were $27,328 thousand, with a diluted EPS of $0.55, while non-GAAP net earnings were $32,460 thousand, resulting in a diluted EPS of $0.65[35] - The adjusted EBITDA for the six months ended November 30, 2025, was $125,538 thousand, compared to $104,649 thousand for the same period in 2024, reflecting a year-over-year increase of approximately 20%[39] - Free cash flow for the three months ended November 30, 2025, was $39,086 thousand, up from $33,892 thousand in the same period of 2024, indicating a growth of about 15%[42] - The operating cash flow conversion for the six months ended November 30, 2025, was 148%, compared to 172% for the same period in 2024[42] Segment Performance - Building Products segment net sales increased by 31.9% to $207.5 million, driven by higher volumes and contributions from Elgen Manufacturing[14] - Consumer Products segment generated net sales of $119.9 million, a 2.7% increase over the prior year quarter[13] - The Building Products segment reported net sales of $207,528 thousand for the three months ended November 30, 2025, a 32.0% increase from $157,298 thousand in the same period of 2024[31] Assets and Liabilities - Total debt at quarter end was $305.3 million, with no borrowings under the revolving credit facility[12] - Total assets as of November 30, 2025, were $1,753,333 thousand, an increase from $1,695,152 thousand as of May 31, 2025[27] - Cash and cash equivalents decreased to $180,288 thousand from $250,075 thousand at the beginning of the period[29] Dividends and Shareholder Returns - The company declared a quarterly dividend of $0.19 per common share, payable on March 27, 2026[4] - Dividends declared per common share increased to $0.19 for the three months ended November 30, 2025, compared to $0.17 in the same period of 2024[25] Acquisitions and Investments - The company announced an agreement to acquire LSI Group for approximately $205 million, expected to close in January 2026[4][15] - The company’s investment in property, plant, and equipment for the three months ended November 30, 2025, was $12,432 thousand, compared to $15,161 thousand in the same period of 2024[42] Other Financial Metrics - Adjusted EBITDA margin for the consolidated results was 18.5% for the three months ended November 30, 2025, down from 20.5% in the same period of 2024[31] - The adjusted EBITDA margin for the three months ended November 30, 2025, was 18.5%, down from 20.5% in the same period of 2024[39] - The company reported a restructuring and other expense of $1,644 thousand for the three months ended November 30, 2025, which impacted the GAAP earnings[35] - The loss on the partial sale of investment in SES was $2,950 thousand for the three months ended November 30, 2025, affecting the overall earnings[35] - The net earnings attributable to controlling interest for the six months ended November 30, 2025, was $62,476 thousand, compared to $52,513 thousand in 2024, representing a year-over-year increase of approximately 19%[42]

Worthington Enterprises Reports Second Quarter Fiscal 2026 Results COLUMBUS, Ohio (December 16, 2025) – Worthington Enterprises Inc. (NYSE: WOR), a designer and manufacturer of market-leading consumer and building products that improve everyday life by elevating spaces and experiences, today reported results for its fiscal 2026 second quarter ended November 30, 2025. Recent Developments and Second Quarter Highlights (all comparisons to the second quarter of fiscal 2025): "We delivered solid financial result ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _____________ Commission File Number: 001-41532 HUDSON ACQUISITION I CORP. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 86- 271284 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to _____________ Commission File Number: 001-41532 HUDSON ACQUISITION I CORP. (Exact Name of Registrant as Specified in Its Charter) | Delaware | 86- 271284 ...

Exhibit 99.1 CSPi Delivers 11% Revenue Growth and Expands Gross Margin During Fiscal Year 2025 Fourth Quarter from Prior Fiscal Year Fourth Quarter; Enters Fiscal 2026 with New Customer Momentum Across Business Units AZT PROTECTTM Continues to Increase Customer Base; Brand Awareness Initiatives Raise Expectations for Higher Customer Adoption During Fiscal 2026 Conference Call Today at 10 a.m. ET LOWELL, Mass., December 16, 2025 – CSP Inc. (NASDAQ: CSPI), an award-winning provider of security and packet capt ...